Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Karl-Fredrik Eriksson

Associate professor

Default user image.

Increased plasma endothelin-1 and intraplatelet cyclic guanosine monophosphate in men with disturbed glucose metabolism

Author

  • I. Anwaar
  • A. Gottsäter
  • K. F. Eriksson
  • L. Jacobsson
  • F. Lindgärde
  • I. Mattiasson

Summary, in English

Plasma endothelin-1, the nitric oxide (NO) mediator intraplatelet cyclic guanosine monophosphate (cGMP), the prostacyclin mediator cyclic adenosine monophosphate (cAMP) and the macrophage derived inflammatory mediator plasma neopterin were measured in men with Type 2 diabetes mellitus (n = 91), impaired glucose tolerance (IGT; n = 51), previously abnormal glucose tolerance (PAGT; n = 20), and 34 healthy control men. Plasma endothelin-1 was higher in men with Type 2 diabetes mellitus than in controls [4.1 (1.0-14.3) vs. 2.1 (0.2-8.7) ng/l; P < 0.001). Intraplatelet cGMP was higher in men with PAGT [0.84 (0.57-2.76) pmol/109 platelets; P < 0.05], IGT [0.85 (0.48-3.53); P < 0.001] and Type 2 diabetes mellitus [0.90 (0.47-3.86); P < 0.001] than in controls [0.70 (0.42-1.70]. No differences existed between groups concerning intraplatelet cAMP or plasma neopterin. Plasma endothelin-1 correlated with fasting plasma glucose (r = 0.33; P < 0.001) and HbA1(c) (r = 0.29; P < 0.001). In conclusion, elevated plasma endothelin-1 in Type 2 diabetes mellitus and its relationship to glucose and HbA1(c) suggest a putative role for endothelin-1 in diabetic endothelial cell damage. Increased cGMP indicating enhanced production/activity of NO suggests that factors other than reduced NO activity contribute to enhanced platelet aggregation in diabetes. (C) 2000 Elsevier Science Ireland Ltd.

Department/s

  • Genomics, Diabetes and Endocrinology
  • Vascular Diseases - Clinical Research

Publishing year

2000-10-01

Language

English

Pages

127-136

Publication/Series

Diabetes Research and Clinical Practice

Volume

50

Issue

2

Document type

Journal article

Publisher

Elsevier

Topic

  • Endocrinology and Diabetes

Keywords

  • cGMP
  • Endothelin-1
  • IGT
  • Neopterin
  • Type 2 diabetes

Status

Published

Research group

  • Genomics, Diabetes and Endocrinology
  • Vascular Diseases - Clinical Research

ISBN/ISSN/Other

  • ISSN: 0168-8227